The development of a long-acting delivery system for D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2 (RC-160), an octapeptide analog of somatostatin, required the establishment of a method for determining the concentration of this analog in serum during treatment. A sensitive and specific radioimmunoassay (RIA) for RC-160 was developed and used for following the rate of liberation of this peptide from microcapsules of poly(DL-lactide-coglycolide). Antibodies were generated in a rabbit against RC-160 coinugated to bovine serum albumin with glutaraldehyde. At an antiserum dilution of 1:100,000, the antibodies bound approximately 25% of added radiolabeled RC-160. Somatostatin octapeptide analogs that had a disulfide bridge showed crossreactivity with the antiserum, but analogs without the disulfide bridge and other peptides tested did not crossreact. The minimum detectable dose of RC-160 was 10 pg. Intra-and interassay coefficients of variation ranged from 9.1% to 12.8% and from 14% to 30%, respectively. The RIA was suitable for direct determination of RC-160 in serum. Eleven prototype batches of microcapsules were tested in rats, and the rate of release of the analog from the microcapsules was followed. An improved batch of microcapsules made from RC-160 pamoate maintained high serum levels of RC-160 for more than 30 days after intramuscular injection. The RIA should be of value for monitoring levels of this analog in serum during long-term therapy.
Lys-Val-C's-Thr-NH2 (RC-121) show a high potency and a long duration of action in tests for inhibition of growth hormone release and much lower activity for suppression of insulin, glucagon, and gastric acid secretion (1, 2) . This indicates a marked selectivity in their biological actions, which could make them useful for the treatment of endocrinerelated diseases such as type I diabetes mellitus and diabetic retinopathy.
There is also experimental evidence that somatostatin analogs might be used to treat pancreatic cancer (3) by inhibiting the release of gastrointestinal hormones such as secretin, gastrin, and cholecystokinin or by stimulating the dephosphorylation of membrane receptors for the epidermal growth factor (4) . In addition, somatostatin analogs of this class inhibit the growth of experimental prostate and mammary tumors by suppressing the levels of prolactin, growth hormone, and insulin-like growth factor I (IGF-I, somatomedin C) (5) and could be used as adjuncts to therapy with analogs of luteinizing hormone-releasing hormone (LH-RH).
Thus, therapeutic application of these analogs in the treatment of various hormone-sensitive tumors is likely (6) .
The use of RC-160 and related analogs for the therapy of hormone-dependent tumors and endocrine disorders would be greatly enhanced by delayed delivery systems capable of maintaining controlled levels of the peptide over an extended period of time. Consequently, we started the development of such a long-acting delivery system for RC-160 by using a formulation in microcapsules of poly(DL-lactide-coglycolide) similar to that successfully employed for [D-Trp6]LH-RH (7, 8) . This polymer is biodegradable and biocompatible with living tissue. The injectable microcapsules were designed for a controlled release of the peptide over a 30-day period. This approach is convenient and efficacious and permits once-amonth administration of microcapsules. To monitor the release of RC-160 from these microcapsules, we have developed a rapid, sensitive, and specific RIA for this peptide. This paper describes the establishment of the RIA and the development of a delayed delivery system for RC-160.
MATERIALS AND METHODS
Analog and Microcapsules. RC-160 was synthesized by Nova Biochem (Laufelfingen, Switzerland) in the form of the acetate or pamoate salt. Microcapsules of RC-160 were prepared by a phase-separation process. The peptide was dispersed in a solution of poly(DL-lactide-coglycolide). A phase inducer for the copolymer was added to coacervate the polymer. The coacervate droplets, containing the drug, were hardened to obtain the microcapsules, which were sieved. Prototype batches were made by one of us (P.O.) at Cytotech (Martigny, Switzerland). The microcapsule product was a free-flowing powder of spherical particles consisting of RC-160 acetate (batches 1-10) or pamoate (batch 11) (2-6%, wt/wt), dispersed throughout a polymeric matrix of poly(DLlactide-coglycolide) (94-98%). The microcapsules were sterilized with a 2.5-megarad (0.025-megagray) dose of 'y radiation.
Immunogen Preparation. A modification of a coupling method described elsewhere (9) was used. One milligram of RC-160 in 1.0 ml of 0.01 M acetic acid was mixed with 1. After centrifugation at 2900 x g for 20 min at 4°C, the supernatants were decanted and the radioactivity of the precipitates was measured in a 10-detector y scintillation counter (Micromedic Systems, Horsham, PA). All samples were assayed in duplicate. RIA Validation. Assay sensitivity, specificity, accuracy, and precision, as well as the effects of the presence of serum in the assay system, were evaluated. The stability of the peptide in serum to repeated freeze-thaw cycles and to exposure to elevated temperature was also studied.
Sensitivity. Twenty replicates of the zero standard were assayed in one assay run.
Specificity. Various analogs and fragments of somatostatin were assayed at concentrations varying by 4 orders of magnitude. Several other peptide hormones were also tested.
Accuracy. Fractional-recovery studies were performed with rat and human serum by adding RC-160 to a pool of serum at various dose levels and assaying the mixture. Dilutional parallelism was evaluated by making serial dilureplicates of each pool were also assayed in five assay runs to evaluate interassay precision.
Effect of serum. Various amounts (10, 25, Blood samples of about 0.5 ml were taken from the jugular vein daily for the first 7 days and periodically thereafter for 20-40 days after the injection. The serum was collected and stored frozen at -20°C until assayed for RC-160.
Some serum samples were also assayed for IGF-I by a modification of the method of Daughaday et al. (11) . Five microliters of rat serum was extracted with 200 ,ul of 0.3 M HCl in ethanol. The supernatant was diluted with 0.2 M Tris buffer (pH 7.4), and an aliquot equivalent to 0.2 pul of serum was taken for the assay. IGF-I (a gift from C. H. Li) was iodinated by the chloramine-T method and purified by HPLC; the same antigen was used for the standard curve at concentrations from 16 to 4000 pg per tube. Rabbit anti-IGF-I antiserum (provided by the National Hormone and Pituitary Program) was used at an initial dilution of 1:4000. The reactants were incubated overnight at room temperature, and bound and free antigens were separated by a polyethylene glycol-facilitated double-antibody method.
Statistical evaluations of all data were made with Duncan's new multiple range test (12) . Precision. Ten replicates of pools of rat serum containing RC-160 at three levels (low, medium, and high pools) were assayed in one run to determine intraassay precision. Three Medical Sciences: Mason-Garcia et al. Radioiodination. By using the chloramine-T method to iodinate RC-160, we were able to achieve an average specific activity of 351 uCi/,g (range, 281-460 ,uCi).
Purification Accuracy. In the fractional-recovery study (Table 2) , the recovery of RC-160 from rat serum was 118-136%, and from human serum it was 122-140%. In the dilutional-parallelism study (Fig. 2) , good parallelism was demonstrated between the regression line for the RC-160 standard and the regression line for the RC-160-containing serum.
Precision. The precision study (Table 3) showed intrassay coefficients of variation that ranged from 9%6 to 12%. Interassay variance ranged from 14% to 30%. Effect of serum. The addition of 50 ,ul of serum to the incubation mixture produced a shift to the right in the standard curve and a decrease in Bo (Fig. 3) .
Stability ofpeptide. There were no significant differences in the mean levels of RC-160 measured in pooled serum (52.0 ± 7.3 pg, mean ± SD, n = 10), after five freeze-thaw cycles (46.4 ± 13.3 pg, n = 10) or after incubation at 37°C for up to 3 hr (52.5 ± 9.2 pg, n = 10).
RC-160 Levels After Administration of Long-Acting Microcapsules to Rats. Eleven batches of microcapsules containing RC-160 have been evaluated for release of the peptide by monitoring serum levels over a period of several weeks in rats injected with these microcapsules. In several of the batches tested, there was a pronounced "burst" effect, with large amounts of peptide being released from the microcapsules during the first 3-4 days after injection. Serum levels of RC-160 then declined from these peak values, reaching nearly Since RC-160 is a small peptide, it can be bound to macromolecular components of serum, as are LH-RH and its analogs (14, 15) . Therefore, to measure RC-160 in serum requires strategies designed to overcome interference in the RIA produced by those peptide-binding proteins. There are several possible approaches to this problem. The first of these is extraction, in which ethanol or methanol is used to precipitate serum proteins, followed by assay of the peptide in the evaporated and reconstituted alcoholic extract. This did not prove feasible for use in this RIA, as RC-160 is not easily soluble in neutral-buffered solutions, making reconsti- tution of the extract difficult and resulting in low recoveries (data not shown). The second strategy involves the use of a small sample volume to reduce the interference from serum binding proteins. This method was successfully used in our RIA for the D-Trp6 analog of LH-RH (15) , but the sensitivity of the RC-160 RIA was not sufficient to permit its use. The third approach to solving this problem consists of adding an aliquot of pooled serum, equivalent to the volume of the unknown samples, to the standard-curve tubes. This is the most common method used to overcome this problem in the case of commercially available RIA kits that permit "direct" assay of steroids, various drugs, or small peptides (16) . This tactic is useful only if the pooled serum is free of crossreacting peptides. As RC-160 is an exogenous peptide, we were not concerned with interference from endogenous materials in serum. In addition, there was virtually no crossreactivity with somatostatin or other naturally occurring peptides. Therefore, we chose to use this method for our RIA system.
The rates of release of RC-160 from the earlier batches of Medical Sciences: Mason-Garcia et al.
microcapsules were uneven, and a marked fall in the serum levels of the peptide occurred earlier than the targeted 30-day interval. The release pattern of the improved batch (no. 11) showed the liberation of acceptable serum levels of RC-160 in a continuous fashion over the time period studied (Fig. 4) . The patterns of release were similar to those seen with related formulations of an analog of LH-RH (15) . The serum levels of RC-160 produced by the released microcapsules were therapeutically effective as demonstrated by the continued suppression of IGF-I in serum throughout the course of the treatment (Fig. 4) . Diminished IGF-I levels reflect suppression of pituitary release ofgrowth hormone (17) and have also been seen in previous studies with RC-160 (5). The present formulation of the microcapsules, which can be conveniently injected at monthly intervals, should have a higher efficacy than discontinuous administration and would ensure patient compliance. This use of microcapsules might allow the establishment of continuous therapeutic levels of RC-160 and permit new approaches in the management of pancreatic cancer and other malignancies and conditions (6, 18, 19) . Microcapsules of RC-160 could also be tried in combination with LH-RH agonists for the treatment of breast and prostate cancer (5, 6, 18) .
